Neurocognitive Effects of Bilateral STN Versus GPi DBS in Parkinson's Disease Patients With MCI (DBS)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01870518 |
Recruitment Status :
Terminated
(Lack of enrollment)
First Posted : June 6, 2013
Last Update Posted : February 10, 2016
|
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Parkinson's Disease Mild Cognitive Impairment Dementia | Device: Bilateral GPi DBS Device: Bilateral STN DBS | Not Applicable |
Deep brain stimulation (DBS) of the globus pallidus interna (GPi) or subthalamic nucleus (STN) has been accepted as the surgical treatment of choice for patients with advanced Parkinson's Disease (PD), demonstrating improvements in motor function that exceed those achieved by medical management alone. Unfortunately, a paucity of data exist comparing non-motor outcomes between DBS of the available targets. Specifically, a high prevalence of concurrent cognitive dysfunction or early dementia exists in PD patients, and it is unclear whether DBS target selection may have differential effects with regards to cognitive outcomes in PD patients with early evidence of mild cognitive impairment Previous studies indicate that stimulation of either the GPi or STN is associated with decrements in patients' verbal fluency, visuospatial memory, as well as overall cognitive decline, but those patients were randomized without consideration for baseline neurocognitive performance and it is unclear whether these effects are due to treatment or rather the natural history of these patients.
In addition to the clinical arm of this trial, another secondary goal is to evaluate several biomarkers obtained from blood and cerebrospinal in order to determine their utility if any as prognosticators of patient cognitive and motor outcomes. Specifically, we will be evaluating levels of amyloid 1-42, total tau, phosphorylated tau 181, and brain derived neurotrophic factor in the cerebrospinal fluid as well as genotyping the apolipoprotein-E gene. These proteins and genotypes are still currently under investigation as potential biomarkers for dementia as well as neuroplasticity.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 13 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Care Provider, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | Neurocognitive Effects of Bilateral Subthalamic Nucleus Versus Globus Pallidus Interna Deep Brain Stimulation in Parkinson's Disease Patients With Mild Cognitive Impairment |
Study Start Date : | April 2013 |
Actual Primary Completion Date : | February 2016 |
Actual Study Completion Date : | February 2016 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Parkinson's patients with MCI
Procedure: deep brain stimulation surgery
|
Device: Bilateral GPi DBS Device: Bilateral STN DBS |
Active Comparator: Parkinson's patients without MCI
Procedure: deep brain stimulation surgery
|
Device: Bilateral GPi DBS Device: Bilateral STN DBS |
- Neurocognitive Function [ Time Frame: 6 months post-operative ]By focusing on patients with MCI, our primary aim will be to detect whether STN or GPi DBS incur target specific impacts on patients' subsequent neurocognitive function.Patients will undergo neuropsychological testing pre-operatively and again at six months post-operatively. Patient's will also undergo a Montreal Cognitive Assessment at specified intervals: pre-operatively, 3weeks, 6 weeks and 6 months post-operatively.
- Functional motor improvements [ Time Frame: 6 month post-operative ]The secondary aim will be measure functional motor outcomes in our patients.Patient's will undergo Unified Parkinson's Disease Rating Scale (UPDRS 3 and 4) motor testing pre-operatively in the off medication and on medication states. Patients will be re-tested 6 months post-operatively in the following states: on device / off medication, off device / off medication, on device / on medication.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 21 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- clinical diagnosis of idiopathic Parkinson's disease
- deemed an appropriate candidate for DBS surgery
- Montreal Cognitive Assessment (MoCA) score < 25
- Neuropsychological testing with the diagnosis of Mild Cognitive Impairment
Exclusion Criteria:
- no diagnosis of Parkinson's disease
- not appropriate for DBS surgery

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01870518
United States, Arizona | |
Barrow Neurological Institute / St. Joseph's Hospital & Medical Center | |
Phoenix, Arizona, United States, 85013 |
Principal Investigator: | Francisco A Ponce, MD | Barrow Neurological Institute / St. Joseph's Hospital & Medical Center |
Responsible Party: | St. Joseph's Hospital and Medical Center, Phoenix |
ClinicalTrials.gov Identifier: | NCT01870518 |
Other Study ID Numbers: |
13BN006 |
First Posted: | June 6, 2013 Key Record Dates |
Last Update Posted: | February 10, 2016 |
Last Verified: | February 2016 |
Parkinson's disease Dementia |
Parkinson Disease Dementia Cognitive Dysfunction Parkinsonian Disorders Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases |
Nervous System Diseases Movement Disorders Synucleinopathies Neurodegenerative Diseases Neurocognitive Disorders Mental Disorders Cognition Disorders |